PDCD1 and non-small cell lung carcinoma: For example, Sitravatinib is a multikinase inhibitor that targets all three TAM receptors, and the combination of Sitravatinib with the PD-1 inhibitor Nivolumab is currently in phase II (NCT02954991) and phase III (NCT03906071) clinical trials for non-small cell lung cancer treatment.